RxDoctor Payments DataLook up a doctor →

Robert Nahouraii, MD

Neurology with Special Qualifications in Child Neurology · Concord, NCNPI 1104877224

Payments from drug & device makers

$724,437in general payments, 2019–2025

Across 818 payments — averaging $885.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$199K
  • H. Lundbeck A S$134K
  • GW Research Limited$115K
  • Aquestive Therapeutics, Inc.$47K
  • Pfizer$46K
  • Novartis$45K
  • plus $138K from 54 others
$3,000in research payments, 2019–2025

Across 2 payments — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)68$198,841
H. Lundbeck A S64$133,659
GW Research Limited24$115,275
Aquestive Therapeutics, Inc.59$46,909
Pfizer6$45,875
Novartis13$45,148
Biogen12$36,743
Jazz Pharmaceuticals Inc.30$29,912
Vanda Pharmaceuticals Inc.4$25,542
Alkermes, Inc.14$15,099
Biohaven Pharmaceutical Holding Company Ltd.18$6,972
Greenwich Biosciences, Inc.13$5,007
SK Life Science, Inc.37$4,608
UCB Biosciences Inc.2$2,802
UCB, Inc.64$2,375
Zogenix Inc.4$1,482
Neurelis, Inc.48$1,247
Livanova USA, Inc.17$607
Sumitomo Pharma America, Inc.27$563
Teva Pharmaceuticals USA, Inc.37$492
Sunovion Pharmaceuticals Inc.20$435
Eisai Inc.22$407
Aucta Pharmaceuticals, Inc.22$407
Amneal Pharmaceuticals LLC2$373
Biohaven Pharmaceuticals, Inc.23$301
AstraZeneca(2 entities)11$290
Acadia Pharmaceuticals Inc15$260
EMD Serono, Inc.12$249
Upsher-smith Laboratories LLC11$197
Amgen(2 entities)6$181
Takeda Pharmaceuticals U.S.A., Inc.8$155
Argenx US, Inc.6$150
Neurocrine Biosciences, Inc.6$126
Johnson & Johnson6$112
Corium, LLC5$97
Azurity Pharmaceuticals, Inc.5$92
Mallinckrodt Hospital Products Inc.3$89
Insightec,inc2$80
Banner Life Sciences, LLC4$78
Supernus Pharmaceuticals, Inc.5$73
TG Therapeutics, Inc.3$68
Otsuka America Pharmaceutical, Inc.3$66
Ultragenyx Pharmaceutical Inc.3$65
GE HealthCare3$61
Avion Pharmaceuticals3$57
Biomarin Pharmaceutical Inc.3$53
Acorda Therapeutics, Inc2$47
Catalyst Pharmaceuticals, Inc.3$47
Collegium Pharmaceutical, Inc.2$47
Microtransponder, Inc.1$46
Abbott2$45
Lundbeck LLC2$45
PTC Therapeutics, Inc.2$39
Harmony Biosciences LLC1$33
Sanofi1$32
Avadel CNS Pharmaceuticals, LLC1$31
Travere Therapeutics, Inc.11$29
ANI Pharmaceuticals, Inc.2$28
Arbor Pharmaceuticals, Inc.1$27
Alnylam Pharmaceuticals Inc.1$25

How this compares

$724,437 in reported general payments places this provider in the 95th percentile of 46 neurology with special qualifications in child neurology providers in North Carolina.

See all neurology with special qualifications in child neurology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$1,008
Medicare patients
14
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Concord

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →